Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Pepstatin A: Applied Workflows and Troubleshooting
2026-09-12
Pepstatin A is an aspartic protease inhibitor for connecting enzyme-level inhibition with viral protein processing research, osteoclast differentiation inhibition, and cell-based protease studies. This practical guide covers stock preparation, dose selection, controls, and how to interpret protease results alongside GABAA receptor trafficking experiments.
-
NSC-23766: Strategic Rac1 Inhibition in Cancer
2026-09-11
NSC-23766 trihydrochloride offers translational researchers a mechanistically focused way to interrogate Rac1 activation, breast cancer phenotypes, and BRD4–RAC1 co-targeting. This thought-leadership guide separates established evidence from experimental opportunity and provides a practical framework for biomarker-led validation.
-
Separating Growth Inhibition from Cell Death
2026-09-11
Hannah Schwartz’s dissertation shows that relative viability and fractional viability capture different components of anticancer drug response: proliferative inhibition and cell killing. Its central practical implication is that oncology assays should measure these outcomes separately and across time, particularly when evaluating targeted or anti-angiogenic therapies.
-
WY-14643: PPARα Control of Liver Pyroptosis
2026-09-10
WY-14643 (Pirinixic Acid) is examined here as a mechanistic tool for connecting PPARα activation with hepatic lipid regulation, inflammation, and pyroptosis. The article translates recent cholestatic liver injury findings into practical assay-design decisions while distinguishing class-level evidence from compound-specific conclusions.
-
Renal Blood Flow and K⁺ Channels in Septic Rats
2026-09-10
This study used complementary perfused-kidney and in vivo experiments to determine how potassium-channel blockade alters renal vascular responses to norepinephrine and phenylephrine during experimental sepsis. Its main contribution is showing that channel blockade can worsen renal hypoperfusion when combined with vasoactive drugs, even when the blockers alone do not change baseline renal blood flow.
-
Ceramides Drive RGNNV Infection Through Autophagy
2026-09-09
This study uses global lipidomics and pathway perturbation to show that red-spotted grouper nervous necrosis virus reshapes ceramide metabolism to support replication. Its most important mechanistic finding is that C16-ceramide promotes viral infection partly by enhancing virus-induced autophagy, identifying sphingolipid flux as a potential target for aquaculture virology.
-
Plerixafor: Reframing CXCR4 in Tumor Trafficking
2026-09-09
Plerixafor (AMD3100) is more than a stem cell mobilization reagent: it is a strategic probe for CXCL12/CXCR4-dependent trafficking across tumor, hematopoietic, and inflammatory systems. This article connects platelet extravasation biology with translational experimental design, competitive positioning, and practical workflows.
-
Zoledronic Acid: From Mechanism to Assay Design
2026-09-08
Zoledronic Acid is a nitrogen-containing bisphosphonate used in cancer and bone-disease research. This guide develops a decision-oriented assay framework, using a mechanistic psoriasis study to show how orthogonal validation can improve interpretation without conflating distinct biological systems.
-
Carbohydrate-Decorated Nanoparticles for Macrophage Therapy
2026-09-08
Chen and colleagues developed biodegradable nanoparticles that combine a cationic lipid-like component with carbohydrate-decorated PLGA or PLGA-PEG to improve gene delivery to macrophages. Their comparison of mannose, galactose, dextran, and mixed carbohydrate surfaces shows that nanoparticle composition influences uptake, reporter expression, and the practical performance of macrophage-targeted gene delivery.
-
Dabigatran Assays for Thrombin and CVD Research
2026-09-07
Dabigatran enables controlled, reversible thrombin inhibition across thrombin-generation, TT, aPTT, and PT workflows. This guide connects practical assay design with cardio-cerebrovascular research while addressing formulation, metabolite, and pathway-specific troubleshooting.
-
Matrine, YTHDF1, and Thymoma Stemness
2026-09-07
A 2026 study reports that Matrine reduces stemness-associated behavior and promotes apoptosis in EL-4-B5 thymoma cells, with YTHDF1 and Wnt/β-catenin signaling emerging as candidate mediators. The findings establish a useful in vitro framework for studying thymoma stemness, but the absence of direct m6A measurements, animal experiments, and clinical validation limits mechanistic and translational conclusions.
-
Jasplakinolide: Designing Better Actin Assays
2026-09-05
Jasplakinolide is a potent actin polymerization inducer and F-actin stabilizer for mechanistic cell biology. This guide explains how to convert its direct cytoskeletal activity into better-controlled assays, using chemical-genetic reasoning from jasmonate research to improve interpretation without conflating distinct pathways.
-
(-)-JQ1 in Heterogeneous BET Assays
2026-09-04
(-)-JQ1 is more than an inactive control: this JQ1 stereoisomer helps separate stereospecific BET biology from cell-line-specific stress responses. Learn how to apply it to HPV-associated cancer biology and BRD4 target gene modulation.
-
Gamma-linolenic acid: Applied Research Workflows
2026-09-04
Use Gamma-linolenic acid (GLA) to interrogate LTB4-linked inflammation, cellular stress, and apoptosis with controlled, solvent-aware workflows. A practical comparison with arachidonic acid research helps distinguish established anti-inflammatory applications from emerging nutritional-immunology questions.
-
KU-55933 and the Next Era of ATM Biology
2026-09-03
KU-55933 offers translational researchers a selective way to interrogate ATM signaling, linking DNA damage response research with Akt regulation, cell-cycle control, and cancer biology. This thought-leadership perspective places the compound alongside emerging telomere–mitochondrial findings while clearly separating established evidence from forward-looking hypotheses.